David F. Hale, Director at Conatus Pharmaceuticals Inc (CNAT), bought 22,528 shares at $11.00 ($31K) on 2013-07-30, disclosed to the SEC on 2013-08-01.
Open-market purchase of $31k CNAT by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $0.00 | 19,679 | $0 | 0.0% |
| 2 | $11.00 | 261 | $3K | 9.2% |
| 3 | $11.00 | 2,588 | $28K | 90.8% |
| Total | $1.39 avg | 22,528 | $31K | 100% |
| Filing → |
| ONCT | SELL | 2021-07-02 | $17K | — | Filing → |
| BIOC | SELL | 2020-06-12 | $645 | — | Filing → |
| BIOC | BUY | 2016-10-21 | $200K | — | Filing → |